Erratum: Platelet transfusion for patients with cancer: American society of clinical oncology clinical practice guideline update (Journal of Clinical Oncology (2018) DOI: 10.1200/JCO.2017.76.1734);Platelet transfusion for patients with cancer: American society of clinical oncology clinical practice guideline update

Journal of Clinical Oncology

Volumn 36, Issue 3, 2018, Pages 283-299

  Schiffer, Charles A ^a   Bohlke, Kari ^b   Delaney, Meghan ^c   Hume, Heather ^d   Magdalinski, Anthony J ^e   McCullough, Jeffrey J ^f   Omel, James L ^g   Rainey, John M ^h   Rebulla, Paolo ⁱ   Rowley, Scott D ^j   Troner, Michael B ^k   Anderson, Kenneth C ^l  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b AMERICAN SOCIETY OF CLINICAL ONCOLOGY   (United States)

^c GEORGE WASHINGTON UNIVERSITY   (United States)

^d UNIVERSITY OF MONTREAL   (Canada)

^e Alliance Cancer Specialists   (United States)

^f UNIVERSITY OF MINNESOTA   (United States)

^g University Health Center ^*  (United States)

^h University Health Center   (United States)

ⁱ FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^j HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

^k MIAMI CANCER INSTITUTE   (United States)

^l HARVARD MEDICAL SCHOOL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

RHESUS D ANTIBODY;

ALLOGENEIC STEM CELL TRANSPLANTATION; ALLOIMMUNIZATION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLEEDING; CANCER PATIENT; DISEASE SEVERITY; EVIDENCE BASED MEDICINE; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INVASIVE PROCEDURE; MEDICAL SOCIETY; PLATELET COUNT; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SOLID MALIGNANT NEOPLASM; SYSTEMATIC REVIEW (TOPIC); THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; BLOOD; CONSENSUS; NEOPLASM; ONCOLOGY; PROCEDURES; RISK FACTOR; STANDARDS; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

CONSENSUS; HUMANS; MEDICAL ONCOLOGY; NEOPLASMS; PLATELET TRANSFUSION; RISK FACTORS; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

EID: 85040842209     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2017.18.0088     Document Type: Erratum

References (130)

1. Schiffer CA, Anderson KC, Bennett CL, et al: Platelet transfusion for patients with cancer: Clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 19:1519-1538, 2001
2. Katus MC, Szczepiorkowski ZM, Dumont LJ, et al: Safety of platelet transfusion: Past, present and future. Vox Sang 107:103-113, 2014
3. Kaufman RM, Djulbegovic B, Gernsheimer T, et al: Platelet transfusion: A clinical practice guideline from the AABB. Ann Intern Med 162:205-213, 2015
4. Nahirniak S, Slichter SJ, Tanael S, et al: Guidance on platelet transfusion for patients with hypoproliferative thrombocytopenia. Transfus Med Rev 29:3-13, 2015
5. Shojania KG, Sampson M, Ansari MT, et al: How quickly do systematic reviews go out of date? A survival analysis. Ann Intern Med 147:224-233, 2007
6. Shiffman RN, Michel G, Rosenfeld RM, et al: Building better guidelines with BRIDGE-Wiz: Development and evaluation of a software assistant to promote clarity, transparency, and implementability. J Am Med Inform Assoc 19:94-101, 2012
7. Children’s Cancer and Blood Disorders C17 Guidelines Committee: C17 guideline for platelet transfusion thresholds for pediatric hematology/ oncology patients. http://www.c17.ca/index.php?cID=86
8. Crighton GL, Estcourt LJ, Wood EM, et al: A therapeutic-only versus prophylactic platelet transfusion strategy for preventing bleeding in patients with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation. Cochrane Database Syst Rev 9:CD010981, 2015
9. Estcourt LJ, Desborough M, Hopewell S, et al: Comparison of different platelet transfusion thresholds prior to insertion of central lines in patients with thrombocytopenia. Cochrane Database Syst Rev: CD011771, 2015
10. Estcourt LJ, Ingram C, Doree C, et al: Use of platelet transfusions prior to lumbar punctures or epidural anaesthesia for the prevention of complications in people with thrombocytopenia. Cochrane Database Syst Rev (5):CD011980, 2016
11. Estcourt LJ, Stanworth SJ, Doree C, et al: Comparison of different platelet count thresholds to guide administration of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation. Cochrane Database Syst Rev 11:CD010983, 2015
12. Kumar A, Mhaskar R, Grossman BJ, et al: Platelet transfusion: A systematic review of the clinical evidence. Transfusion 55:1116-1127, quiz 1115, 2015
13. Pavenski K, Rebulla P, Duquesnoy R, et al: Efficacy of HLA-matched platelet transfusions for patients with hypoproliferative thrombocytopenia: A systematic review. Transfusion 53:2230-2242, 2013
14. Vamvakas EC: Is white blood cell reduction equivalent to antibody screening in preventing transmission of cytomegalovirus by transfusion? A review of the literature and meta-analysis. Transfus Med Rev 19:181-199, 2005
15. Vassallo RR, Fung M, Rebulla P, et al: Utility of cross-matched platelet transfusions in patients with hypoproliferative thrombocytopenia: A systematic review. Transfusion 54:1180-1191, 2014
16. Boyum JH, Atwell TD, Schmit GD, et al: Incidence and risk factors for adverse events related to image-guided liver biopsy. Mayo Clin Proc 91: 329-335, 2016
17. Ford PA, Grant SJ, Mick R, et al: Autologous stem-cell transplantation without hematopoietic support for the treatment of hematologic malignancies in Jehovah’s Witnesses. J Clin Oncol 33: 1674-1679, 2015
18. Jia Y, Li W, Liu N, et al: Prevalence of platelet-specific antibodies and efficacy of crossmatch-compatible platelet transfusions in refractory patients. Transfus Med 24:406-410, 2014
19. Krishna SG, Rao BB, Thirumurthi S, et al: Safety of endoscopic interventions in patients with thrombocytopenia. Gastrointest Endosc 80:425-434, 2014
20. Mishima Y, Tsuno NH, Matsuhashi M, et al: Effects of universal vs bedside leukoreductions on the alloimmunization to platelets and the platelet transfusion refractoriness. Transfus Apheresis Sci 52:112-121, 2015
21. Nandagopal L, Veeraputhiran M, Jain T, et al: Bronchoscopy can be done safely in patients with thrombocytopenia. Transfusion 56:344-348, 2016
22. O’Brien KL, Haspel RL, Uhl L: Anti-D alloimmunization after D-incompatible platelet transfusions: A 14-year single-institution retrospective review. Transfusion 54:650-654, 2014
23. Seeff LB, Everson GT, Morgan TR, et al: Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C trial. Clin Gastroenterol Hepatol 8: 877-883, 2010
24. Seftel MD, Growe GH, Petraszko T, et al: Universal prestorage leukoreduction in Canada decreases platelet alloimmunization and refractoriness. Blood 103:333-339, 2004
25. Wallace MJ, Narvios A, Lichtiger B, et al: Transjugular liver biopsy in patients with hematologic malignancy and severe thrombocytopenia. J Vasc Interv Radiol 14:323-327, 2003
26. Weinstein R, Simard A, Ferschke J, et al: Prospective surveillance of D- recipients of D+ apheresis platelets: Alloimmunization against D is not detected. Transfusion 55:1327-1330, 2015
27. Hess JR, Trachtenberg FL, Assmann SF, et al: Clinical and laboratory correlates of platelet alloimmunization and refractoriness in the PLADO trial. Vox Sang 111:281-291, 2016
28. Kaufman RM, Assmann SF, Triulzi DJ, et al: Transfusion-related adverse events in the Platelet Dose study. Transfusion 55:144-153, 2015
29. Heddle NM, Arnold DM, Boye D, et al: Comparing the efficacy and safety of apheresis and whole blood-derived platelet transfusions: A systematic review. Transfusion 48:1447-1458, 2008
30. Whitaker BI, Hinkins S: The 2011 National Blood Collection and Utilization Survey Report. Washington, DC, US Department of Health and Human Services, 2013. http://www.hhs.gov/ash/bloodsafety/2011-nbcus.pdf
31. Whitaker B, Rajbhandary S, Kleinman S, et al: Trends in United States blood collection and transfusion: Results from the 2013 AABB Blood Collection, Utilization, and Patient Blood Management Survey. Transfusion 56:2173-2183, 2016
32. Murphy S, Heaton WA, Rebulla P: Platelet production in the Old World–and the New. Transfusion 36:751-754, 1996
33. Högman CF, Berséus O, Eriksson L, et al: Buffy-coat-derived platelet concentrates: Swedish experience. Transfus Sci 18:3-13, 1997
34. Pietersz RN, Loos JA, Reesink HW: Platelet concentrates stored in plasma for 72 hours at 22 degrees C prepared from buffycoats of citrate-phosphate-dextrose blood collected in a quadruple-bag saline-adenine-glucose-mannitol system. Vox Sang 49:81-85, 1985
35. Eriksson L, Shanwell A, Gulliksson H, et al: Platelet concentrates in an additive solution prepared from pooled buffy coats. In vivo studies. Vox Sang 64: 133-138, 1993
36. Heaton WA, Rebulla P, Pappalettera M, et al: A comparative analysis of different methods for routine blood component preparation. Transfus Med Rev 11: 116-129, 1997
37. 111In and 51Cr. Transfusion 32: 113-120, 1992
38. van Rhenen DJ, Vermeij J, de Voogt J, et al: Quality and standardization in blood component preparation with an automated blood processing technique. Transfus Med 8:319-324, 1998
39. Buchholz DH, Porten JH, Menitove JE, et al: Description and use of the CS-3000 blood cell separator for single-donor platelet collection. Transfusion 23:190-196, 1983
40. Hogge DE, Schiffer CA: Collection of platelets depleted of red and white cells with the “surge pump” adaptation of a blood cell separator. Transfusion 23:177-181, 1983
41. Katz AJ, Genco PV, Blumberg N, et al: Platelet collection and transfusion using the fenwal CS-3000 cell separator. Transfusion 21:560-563, 1981
42. Kuriyan M, Opalka A: Leukoreduced platelet apheresis production with a modified COBE spectra collection protocol. J Clin Apher 10:85-86, 1995
43. McLeod BC, McKenna R, Viernes A, et al: Plateletpheresis with the COBE spectra single needle access option. J Clin Apher 6:24-27, 1991
44. Schoendorfer DW, Hansen LE, Kenney DM: The surge technique: A method to increase purity of platelet concentrates obtained by centrifugal apheresis. Transfusion 23:182-189, 1983
45. Simon TL, Sierra ER, Ferdinando B, et al: Collection of platelets with a new cell separator and their storage in a citrate-plasticized container. Transfusion 31:335-339, 1991
46. Slichter SJ, Kaufman RM, Assmann SF, et al: Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med 362:600-613, 2010
47. AABB: Standards for Blood Banks and Transfusion Services (ed 30). Bethesda, MD, AABB, 2016
48. European Directorate for the Quality of Medicines and Healthcare: Guide to the Preparation, Use and Quality Assurance of Blood Components (ed 18). Strasbourg, France, European Directorate for the Quality of Medicines & HealthCare, 2015.
49. Berséus O, Boman K, Nessen SC, et al: Risks of hemolysis due to anti-A and anti-B caused by the transfusion of blood or blood components containing ABO-incompatible plasma. Transfusion 53:114S-123S, 2013
50. Becker GA, Tuccelli M, Kunicki T, et al: Studies of platelet concentrates stored at 22 C and 4 C. Transfusion 13:61-68, 1973
51. Filip DJ, Aster RH: Relative hemostatic effectiveness of human platelets stored at 4 degrees and 22 degrees C. J Lab Clin Med 91:618-624, 1978
52. Handin RI, Valeri CR: Hemostatic effectiveness of platelets stored at 22 degrees C. N Engl J Med 285:538-543, 1971
53. Holme S, Vaidja K, Murphy S: Platelet storage at 22 degrees C: Effect of type of agitation on morphology, viability, and function in vitro. Blood 52: 425-435, 1978
54. Kunicki TJ, Tuccelli M, Becker GA, et al: A study of variables affecting the quality of platelets stored at “room temperature”. Transfusion 15: 414-421, 1975
55. Scott EP, Slichter SJ: Viability and function of platelet concentrates stored in CPD-adenine (CPDA-1). Transfusion 20:489-497, 1980
56. Bertolini F, Rebulla P, Porretti L, et al: Platelet quality after 15-day storage of platelet concentrates prepared from buffy coats and stored in a glucose-free crystalloid medium. Transfusion 32:9-16, 1992
57. Hogge DE, Thompson BW, Schiffer CA: Platelet storage for 7 days in second-generation blood bags. Transfusion 26:131-135, 1986
58. Murphy S, Kahn RA, Holme S, et al: Improved storage of platelets for transfusion in a new container. Blood 60:194-200, 1982
59. Braine HG, Kickler TS, Charache P, et al: Bacterial sepsis secondary to platelet transfusion: An adverse effect of extended storage at room temperature. Transfusion 26:391-393, 1986
60. Heal JM, Singal S, Sardisco E, et al: Bacterial proliferation in platelet concentrates. Transfusion 26: 388-390, 1986
61. Schiffer CA, Lee EJ, Ness PM, et al: Clinical evaluation of platelet concentrates stored for one to five days. Blood 67:1591-1594, 1986
62. Butler C, Doree C, Estcourt LJ, et al: Pathogen-reduced platelets for the prevention of bleeding. Cochrane Database Syst Rev 3:CD009072, 2013
63. Dunbar NM, Dumont LJ, Szczepiorkowski ZM: How do we implement Day 6 and Day 7 platelets at a hospital-based transfusion service? Transfusion 56: 1262-1266, 2016
64. Łe towska M, Przybylska Z, Piotrowski D, et al: Hemovigilance survey of pathogen-reduced blood components in the Warsaw Region in the 2009 to 2013 period. Transfusion 56:S39-S44, 2016
65. Knutson F, Osselaer J, Pierelli L, et al: A prospective, active haemovigilance study with combined cohort analysis of 19,175 transfusions of platelet components prepared with amotosalen-UVA photochemical treatment. Vox Sang 109:343-352, 2015
66. Moroff G, Friedman A, Robkin-Kline L, et al: Reduction of the volume of stored platelet concentrates for use in neonatal patients. Transfusion 24: 144-146, 1984
67. Simon TL, Sierra ER: Concentration of platelet units into small volumes. Transfusion 24:173-175, 1984
68. Kopolovic I, Ostro J, Tsubota H, et al: A systematic review of transfusion-associated graft-versus-host disease. Blood 126:406-414, 2015
69. Treleaven J, Gennery A, Marsh J, et al: Guidelines on the use of irradiated blood components prepared by the British Committee for Standards in Haematology blood transfusion task force. Br J Haematol 152:35-51, 2011
70. Pritchard AE, Shaz BH: Survey of irradiation practice for the prevention of transfusion-associated graft-versus-host disease. Arch Pathol Lab Med 140: 1092-1097, 2016
71. Delaney M, Wendel S, Bercovitz RS, et al: Transfusion reactions: prevention, diagnosis, and treatment. Lancet 388:2825-2836, 2016
72. Baldwin ML, Ness PM, Scott D, et al: Alloimmunization to D antigen and HLA in D-negative immunosuppressed oncology patients. Transfusion 28:330-333, 1988
73. Goldfinger D, McGinniss MH: Rh-incompatible platelet transfusions–risks and consequences of sensitizing immunosuppressed patients. N Engl J Med 284:942-944, 1971
74. Lichtiger B, Hester JP: Transfusion of Rh-incompatible blood components to cancer patients. Haematologia (Budap) 19:81-88, 1986
75. McLeod BC, Piehl MR, Sassetti RJ: Alloimmunization to RhD by platelet transfusions in autologous bone marrow transplant recipients. Vox Sang 59:185-189, 1990
76. Cid J, Lozano M, Ziman A, et al:Low frequency of anti-D alloimmunization following D+ platelet transfusion: The Anti-D Alloimmunization after D-incompatible Platelet Transfusions (ADAPT) study. Br J Haematol 168:598-603, 2015
77. Dunstan RA, Simpson MB, Rosse WF: Erythrocyte antigens on human platelets. Absence of Rh, Duffy, Kell, Kidd, and Lutheran antigens. Transfusion 24:243-246, 1984
78. Fournel JJ, Zingsem J, Riggert J, et al: A multicenter evaluation of the routine use of a new white cell-reduction apheresis system for collection of platelets. Transfusion 37:487-492, 1997
79. Menitove JE: Immunoprophylaxis for D- patients receiving platelet transfusions from D- donors? Transfusion. 2002;42:136-8. Transfusion 42:1618, 2002
80. Lozano M, Cid J: The clinical implications of platelet transfusions associated with ABO or Rh(D) incompatibility. Transfus Med Rev 17:57-68, 2003
81. Lee D, Contreras M, Robson SC, et al: Recommendations for the use of anti-D immunoglobulin for Rh prophylaxis. Transfus Med 9:93-97, 1999
82. Trial to Reduce Alloimmunization to Platelets Study Group: Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. N Engl J Med 337:1861-1869, 1997
83. Dutcher JP, Schiffer CA, Aisner J, et al: Alloimmunization following platelet transfusion: The absence of a dose-response relationship. Blood 57: 395-398, 1981
84. Dutcher JP, Schiffer CA, Aisner J, et al: Long-term follow-up patients with leukemia receiving platelet transfusions: Identification of a large group of patients who do not become alloimmunized. Blood 58:1007-1011, 1981
85. Duquesnoy RJ, Filip DJ, Rodey GE, et al: Successful transfusion of platelets “mismatched” for HLA antigens to alloimmunized thrombocytopenic patients. Am J Hematol 2:219-226, 1977
86. Claas FH, Smeenk RJ, Schmidt R, et al: Alloimmunization against the MHC antigens after platelet transfusions is due to contaminating leukocytes in the platelet suspension. Exp Hematol 9: 84-89, 1981
87. Dausset J, Rapaport FT: Transplantation antigen activity of human blood platelets. Transplantation 4:182-193, 1966
88. Meryman HT: Transfusion-induced alloimmunization and immunosuppression and the effects of leukocyte depletion. Transfus Med Rev 3:180-193, 1989
89. Slichter SJ, Weiden PL, Kane PJ, et al: Approaches to preventing or reversing platelet alloimmunization using animal models. Transfusion 28: 103-108, 1988
90. Andreu G, Boccaccio C, Klaren J, et al: The role of UV radiation in the prevention of human leukocyte antigen alloimmunization. Transfus Med Rev 6: 212-224, 1992
91. Deeg HJ, Aprile J, Graham TC, et al: Ultraviolet irradiation of blood prevents transfusion-induced sensitization and marrow graft rejection in dogs. Blood 67:537-539, 1986
92. Pamphilon DH, Potter M, Cutts M, et al: Platelet concentrates irradiated with ultraviolet light retain satisfactory in vitro storage characteristics and in vivo survival. Br J Haematol 75:240-244, 1990
93. Vamvakas EC: Meta-analysis of randomized controlled trials of the efficacy of white cell reduction in preventing HLA-alloimmunization and refractoriness to random-donor platelet transfusions. Transfus Med Rev 12:258-270, 1998
94. Hogge DE, McConnell M, Jacobson C, et al: Platelet refractoriness and alloimmunization in pediatric oncology and bone marrow transplant patients. Transfusion 35:645-652, 1995
95. Saarinen UM, Kekomäki R, Siimes MA, et al: Effective prophylaxis against platelet refractoriness in multitransfused patients by use of leukocyte-free blood components. Blood 75:512-517, 1990
96. Saarinen UM, Koskimies S, Myllylä G: Systematic use of leukocyte-free blood components to prevent alloimmunization and platelet refractoriness in multitransfused children with cancer. Vox Sang 65: 286-292, 1993
97. Heddle NM, Klama L, Singer J, et al: The role of the plasma from platelet concentrates in transfusion reactions. N Engl J Med 331:625-628, 1994
98. Bowden RA, Slichter SJ, Sayers M, et al: A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. Blood 86:3598-3603, 1995
99. Simon TL: The collection of platelets by apheresis procedures. Transfus Med Rev 8:132-145, 1994
100. Wandt H, Schaefer-Eckart K, Wendelin K, et al: Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: An open-label, multicentre, rando-mised study. Lancet 380:1309-1316, 2012
101. Stanworth SJ, Estcourt LJ, Powter G, et al: A no-prophylaxis platelet-transfusion strategy for hematologic cancers. N Engl J Med 368:1771-1780, 2013
102. Norfolk DR, Ancliffe PJ, Contreras M, et al: Consensus Conference on Platelet Transfusion, Royal College of Physicians of Edinburgh, 27-28 November 1997. Synopsis of background papers. Br J Haematol 101:609-617, 1998
103. Pisciotto PT, Benson K, Hume H, et al: Prophylactic versus therapeutic platelet transfusion practices in hematology and/or oncology patients. Transfusion 35:498-502, 1995
104. Platelet transfusion therapy. National Institutes of Health Consensus Conference. Transfus Med Rev 1:195-200, 1987
105. Gmür J, Burger J, Schanz U, et al: Safety of stringent prophylactic platelet transfusion policy for patients with acute leukaemia. Lancet 338: 1223-1226, 1991
106. Heckman KD, Weiner GJ, Davis CS, et al: Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukemia: 10,000/microL versus 20,000/ microL. J Clin Oncol 15:1143-1149, 1997
107. Higby DJ, Cohen E, Holland JF, et al: The prophylactic treatment of thrombocytopenic leukemic patients with platelets: A double blind study. Transfusion 14:440-446, 1974
108. Murphy S, Litwin S, Herring LM, et al: Indications for platelet transfusion in children with acute leukemia. Am J Hematol 12:347-356, 1982
109. Rebulla P, Finazzi G, Marangoni F, et al: The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. Gruppo Italiano Malattie Ematologiche Maligne dell’Adulto. N Engl J Med 337:1870-1875, 1997
110. Josephson CD, Granger S, Assmann SF, et al: Bleeding risks are higher in children versus adults given prophylactic platelet transfusions for treatment-induced hypoproliferative thrombocytopenia. Blood 120:748-760, 2012
111. Schiffer CA: What to do if there is no evidence? The issue of surgical procedures in patients with thrombocytopenia. Transfusion 51:2262-2264, 2011
112. O’Connell B, Lee EJ, Schiffer CA: The value of 10-minute posttransfusion platelet counts. Transfusion 28:66-67, 1988
113. Gorgone BC, Andersen JW, Anderson KC: Comparison of 15 min and 1 h post platelet counts in pediatric patients. Transfusion (Bethesda) 26:555, 1986 (abstr S42)
114. Engelfriet CP, Reesink HW, Aster RH, et al: Management of alloimmunized, refractory patients in need of platelet transfusions. Vox Sang 73:191-198, 1997
115. Hogge DE, Dutcher JP, Aisner J, et al: Lym-phocytotoxic antibody is a predictor of response to random donor platelet transfusion. Am J Hematol 14: 363-369, 1983
116. Schiffer CA, O’Connell B, Lee EJ: Platelet transfusion therapy for alloimmunized patients: Selective mismatching for HLA B12, an antigen with variable expression on platelets. Blood 74: 1172-1176, 1989
117. Hussein MA, Lee EJ, Fletcher R, et al: The effect of lymphocytotoxic antibody reactivity on the results of single antigen mismatched platelet transfusions to alloimmunized patients. Blood 87: 3959-3962, 1996
118. O’Connell BA, Lee EJ, Rothko K, et al: Selection of histocompatible apheresis platelet donors by cross-matching random donor platelet concentrates. Blood 79:527-531, 1992
119. Nagasawa T, Kim BK, Baldini MG: Temporary suppression of circulating antiplatelet alloan-tibodies by the massive infusion of fresh, stored, or lyophilized platelets. Transfusion 18:429-435, 1978
120. Schiffer CA, Hogge DE, Aisner J, et al: High-dose intravenous gammaglobulin in alloimmunized platelet transfusion recipients. Blood 64:937-940, 1984
121. Lee EJ, Norris D, Schiffer CA: Intravenous immune globulin for patients alloimmunized to random donor platelet transfusion. Transfusion 27: 245-247, 1987
122. Kickler T, Braine HG, Piantadosi S, et al: A randomized, placebo-controlled trial of intravenous gammaglobulin in alloimmunized thrombocytopenic patients. Blood 75:313-316, 1990
123. Hogge DE, Dutcher JP, Aisner J, et al: The ineffectiveness of random donor platelet transfusion in splenectomized, alloimmunized recipients. Blood 64:253-256, 1984
124. Bensinger WI, Buckner CD, Clift RA, et al: Plasma exchange for platelet alloimmunization. Transplantation 41:602-605, 1986
125. Mead H, Cartwright-Smith L, Jones K, et al: Racial and Ethnic Disparities in U.S. Health Care: A Chartbook. New York, NY, The Commonwealth Fund, 2008.
126. US Cancer Statistics Working Group: United States Cancer Statistics: 1999-2012 Incidence and Mortality Web-based Report. Atlanta, GA, US Department of Health and Human Services, Centers for Disease Control and Prevention, and National Cancer Institute, 2015
127. Howlader N, Noone AM, Krapcho M, et al: SEER Cancer Statistics Review, 1975-2013. Bethesda, MD, National Cancer Institute. https://seer.cancer.gov/archive/csr/1975_2013/
128. American Cancer Society: Cancer Facts and Figures for African Americans 2016-2018. Atlanta, GA, American Cancer Society, 2016.
129. Ferrell BR, Temel JS, Temin S, et al: Integration of palliative care into standard oncology care: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 35:96-112, 2017
130. Gilligan T, Coyle N, Frankel RM, et al: Patient-clinician communication: American Society of Clinical Oncology Consensus Guideline. J Clin Oncol 35:3618-3632, 2017